On receptor inhibitors and chemotherapy.
Ryan
P D
PD
Chabner
B A
BA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D029742:Caenorhabditis elegans Proteins; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000077156:Gefitinib; D015801:Helminth Proteins / Q000378:metabolism; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D029742:Caenorhabditis elegans Proteins; D000068818:Cetuximab; D066246:ErbB Receptors; D000077156:Gefitinib; D015801:Helminth Proteins; D008024:Ligands; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C079744:her-1 protein, C elegans